Progression-free survival at 24 months based on cytogenetic response at 6 months. Patients who achieve complete cytogenetic remission (CCR) have significantly lower rates of progression at 24 months than patients who have no significant cytogenetic response. IRIS/0106 trial data.

O’Brien Figure 3B. Progression-free survival divided into cohorts based on time to achieve complete cytogenetic remission (CCR). This analysis indicates that patients who take up to, say, 12 months to achieve CCR have similar progression-free survival to those who respond rapidly, i.e., within the first 3 months of treatment. IRIS/0106 trial data.